883.40EUR-0.20%Mkt Cap: 60.19B $P/E: 39.10Today
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART fo…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap60.19B $
Enterprise Value54.59B $
Revenue (TTM)5.78B $
Gross Profit4.02B $
Net Income (TTM)1.40B $
Revenue/Share93.38 USD
Last Price883.40 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.9K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINNL0010832176
Valuation
P/E (Trailing)39.10
P/E (Forward)28.86
PEG1.61
EV/EBITDA31.14
EV/Revenue9.45
P/S10.36
P/B7.68
EPS (TTM)22.64
EPS (Forward)30.67
52W Range
564.2098% of range891.20
52W High891.20 EUR
52W Low564.20 EUR
Profitability
Gross Margin89.15%
Oper. Margin31.99%
EBITDA Margin30.34%
Profit Margin31.11%
ROE17.64%
ROA14.88%
Growth
Revenue Growth59.30%
Earnings Growth95.20%
Cash Flow & Leverage
Operating CF744.77M $
CapEx (TTM)121.39M $
FCF Margin14.33%
FCF Yield1.38%
Net Debt-5.58B $
Net Debt/EBITDA-3.18
Balance Sheet
Debt/Equity0.01
Current Ratio5.12
Quick Ratio4.52
Book Value/Sh115.30 EUR
Cash/Share82.89 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)933.15 EUR
Upside (mean)+5.6%
Target Range769.53 EUR – 1237.98 EUR
€769.53+5.6% to mean€1237.98
# Analysts15
Ownership
Shares Out.62.56M
Float62.43M
Insiders0.02%
Institutions48.03%
Technical
SMA 50778.10 (+13.5%)
SMA 200719.82 (+22.7%)
Beta-0.04
S&P 52W Chg18.16%
Avg Vol (30d)82.45K
Avg Vol (10d)80.44K
Technical Indicators
RSI (14)69.4
MACD22.8433
MACD Signal7.2309
MACD Hist.+15.6124
BB Upper884.28 EUR
BB Middle782.42 EUR
BB Lower680.56 EUR
BB Width26.04%
ATR (14)31.30 EUR
Vol Ratio (20d)0.66x